ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that abstracts detailing the clinical response of blepharoconjunctivitis patients treated with dexamethasone formulated in DuraSite® and the safety of bromfenac formulated in DuraSite on ocular tissues have been accepted for presentation at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1–5, 2011 in Fort Lauderdale, Florida. DuraSite, InSite’s proprietary polymer-based technology, extends the duration of drug residence on the surface of the eye to facilitate better penetration, thereby improving efficacy, safety and dosing frequency.
